Impact of Lofexidine on Stress, Craving and Opioid Use
Recruiting
National Institute on Drug Abuse (NIDA)
Phase 2
2019-06-26
Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be
randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks,
they will complete a human laboratory stress task and scripted opioid imagery task.
Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be
used to monitor stress, craving and use in the natural environment.
Impact of Lofexidine on Stress, Craving and Opioid Use
Recruiting
National Institutes of Health (NIH)
Phase 2
2019-06-26
Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be
randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks,
they will complete a human laboratory stress task and scripted opioid imagery task.
Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be
used to monitor stress, craving and use in the natural environment.
Impact of Lofexidine on Stress, Craving and Opioid Use
Recruiting
Medical University of South Carolina
Phase 2
2019-06-26
Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be
randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks,
they will complete a human laboratory stress task and scripted opioid imagery task.
Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be
used to monitor stress, craving and use in the natural environment.
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Completed
US WorldMeds LLC
Phase 2
2019-09-01
This is an open-label pilot trial to evaluate the safety and tolerability of lofexidine in
the management of opioid withdrawal symptoms while initiating outpatient treatment with
naltrexone. The initiation procedure will be a flexible detoxification lasting 2 to 10 days
concluding with the injection of XR-Naltrexone (Vivitrol). Vivitrol is a long-acting
injection that contains enough medicine to last for one month blocking the effects of
opioids.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
